Aptamer-mediated CRISPR-Cas9 delivery for precision oncology: integrating molecular targeting, intracellular trafficking, and nanocarrier engineering
Cancer therapy remains constrained by insufficient molecular specificity, intratumoral heterogeneity, and the emergence of therapeutic resistance that limit durable clinical responses. CRISPR Cas9 genome editing offers an unprecedented opportunity to directly reprogram oncogenic drivers, tumor suppressor pathways, and...